Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 945


A simple and robust real-time qPCR method for the detection of PIK3CA mutations.

Alvarez-Garcia V, Bartos C, Keraite I, Trivedi U, Brennan PM, Kersaudy-Kerhoas M, Gharbi K, Oikonomidou O, Leslie NR.

Sci Rep. 2018 Mar 9;8(1):4290. doi: 10.1038/s41598-018-22473-9.


Recurrent extraneural sonic hedgehog medulloblastoma exhibiting sustained response to vismodegib and temozolomide monotherapies and inter-metastatic molecular heterogeneity at progression.

Petrirena GJ, Masliah-Planchon J, Sala Q, Pourroy B, Frappaz D, Tabouret E, Graillon T, Gentet JC, Delattre O, Chinot O, Padovani L.

Oncotarget. 2018 Jan 3;9(11):10175-10183. doi: 10.18632/oncotarget.23699. eCollection 2018 Feb 9.


Association between PIK3CA alteration and prognosis of gastric cancer patients: a meta-analysis.

Li H, Chen S, Li H, Cui J, Gao Y, Wu D, Luan S, Qin Y, Zhai T, Liu D, Huo Z.

Oncotarget. 2018 Jan 2;9(7):7651-7659. doi: 10.18632/oncotarget.23871. eCollection 2018 Jan 26.


Kinase-targeted cancer therapies: progress, challenges and future directions.

Bhullar KS, Lagarón NO, McGowan EM, Parmar I, Jha A, Hubbard BP, Rupasinghe HPV.

Mol Cancer. 2018 Feb 19;17(1):48. doi: 10.1186/s12943-018-0804-2. Review.


20(S)-Protopanaxadiol induces apoptosis in human hepatoblastoma HepG2 cells by downregulating the protein kinase B signaling pathway.

Lu Z, Xu H, Yu X, Wang Y, Huang L, Jin X, Sui D.

Exp Ther Med. 2018 Feb;15(2):1277-1284. doi: 10.3892/etm.2017.5594. Epub 2017 Dec 5.


PIK3CA and TP53 mutations predict overall survival of stage II/III colorectal cancer patients.

Li AJ, Li HG, Tang EJ, Wu W, Chen Y, Jiang HH, Lin MB, Yin L.

World J Gastroenterol. 2018 Feb 7;24(5):631-640. doi: 10.3748/wjg.v24.i5.631.


PI3K/mTOR inhibition promotes the regression of experimental vascular malformations driven by PIK3CA-activating mutations.

di Blasio L, Puliafito A, Gagliardi PA, Comunanza V, Somale D, Chiaverina G, Bussolino F, Primo L.

Cell Death Dis. 2018 Jan 19;9(2):45. doi: 10.1038/s41419-017-0064-x.


Pik3ca is required for mouse uterine gland development and pregnancy.

Chang HJ, Shin HS, Kim TH, Yoo JY, Teasley HE, Zhao JJ, Ha UH, Jeong JW.

PLoS One. 2018 Jan 18;13(1):e0191433. doi: 10.1371/journal.pone.0191433. eCollection 2018.


The Role of Class IA Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunits in Glioblastoma.

Pridham KJ, Varghese RT, Sheng Z.

Front Oncol. 2017 Dec 15;7:312. doi: 10.3389/fonc.2017.00312. eCollection 2017. Review.


The eIF4E2-Directed Hypoxic Cap-Dependent Translation Machinery Reveals Novel Therapeutic Potential for Cancer Treatment.

Melanson G, Timpano S, Uniacke J.

Oxid Med Cell Longev. 2017;2017:6098107. doi: 10.1155/2017/6098107. Epub 2017 Nov 26. Review.


Phytochemicals and PI3K Inhibitors in Cancer-An Insight.

Suvarna V, Murahari M, Khan T, Chaubey P, Sangave P.

Front Pharmacol. 2017 Dec 14;8:916. doi: 10.3389/fphar.2017.00916. eCollection 2017. Review.


A Rare Case of Intraductal Tubulopapillary Neoplasm of the Pancreas Rupturing and Causing Acute Peritonitis.

Umemura A, Ishida K, Nitta H, Takahara T, Hasegawa Y, Makabe K, Sasaki A.

Case Rep Gastroenterol. 2017 Nov 2;11(3):661-666. doi: 10.1159/000481935. eCollection 2017 Sep-Dec.


Functional characterization of a novel somatic oncogenic mutation of PIK3CB.

Whale AD, Colman L, Lensun L, Rogers HL, Shuttleworth SJ.

Signal Transduct Target Ther. 2017 Dec 22;2:17063. doi: 10.1038/sigtrans.2017.63. eCollection 2017.


Econazole nitrate inhibits PI3K activity and promotes apoptosis in lung cancer cells.

Dong C, Yang R, Li H, Ke K, Luo C, Yang F, Shi XN, Zhu Y, Liu X, Wong MH, Lin G, Wang X, Leung KS, Kung HF, Chen C, Lin MC.

Sci Rep. 2017 Dec 21;7(1):17987. doi: 10.1038/s41598-017-18178-0.


Primary parotid adenocarcinoma metastasis to the spleen with PIK3CA mutation: cytological findings and review of the literature.

Inouye CM, Anagnostou V, Li QK.

Int J Clin Exp Pathol. 2017;10(5):5999-6005. Epub 2017 May 15.


PIK3CAH1047R-induced paradoxical ERK activation results in resistance to BRAFV600E specific inhibitors in BRAFV600E PIK3CAH1047R double mutant thyroid tumors.

Roelli MA, Ruffieux-Daidié D, Stooss A, ElMokh O, Phillips WA, Dettmer MS, Charles RP.

Oncotarget. 2017 Oct 11;8(61):103207-103222. doi: 10.18632/oncotarget.21732. eCollection 2017 Nov 28.


Separation of low and high grade colon and rectum carcinoma by eukaryotic translation initiation factors 1, 5 and 6.

Golob-Schwarzl N, Schweiger C, Koller C, Krassnig S, Gogg-Kamerer M, Gantenbein N, Toeglhofer AM, Wodlej C, Bergler H, Pertschy B, Uranitsch S, Holter M, El-Heliebi A, Fuchs J, Punschart A, Stiegler P, Keil M, Hoffmann J, Henderson D, Lehrach H, Reinhard C, Regenbrecht C, Schicho R, Fickert P, Lax S, Haybaeck J.

Oncotarget. 2017 Sep 5;8(60):101224-101243. doi: 10.18632/oncotarget.20642. eCollection 2017 Nov 24.


PIK3CA mutations are associated with increased tumor aggressiveness and Akt activation in gastric cancer.

Kim JW, Lee HS, Nam KH, Ahn S, Kim JW, Ahn SH, Park DJ, Kim HH, Lee KW.

Oncotarget. 2017 Jun 28;8(53):90948-90958. doi: 10.18632/oncotarget.18770. eCollection 2017 Oct 31.


Molecular Landscape and Treatment Options for Patients with Metastatic Colorectal Cancer.

Miyamoto Y, Zhang W, Lenz HJ.

Indian J Surg Oncol. 2017 Dec;8(4):580-590. doi: 10.1007/s13193-016-0543-z. Epub 2016 Jul 27. Review.


Oncogenic PIK3CA induces centrosome amplification and tolerance to genome doubling.

Berenjeno IM, Piñeiro R, Castillo SD, Pearce W, McGranahan N, Dewhurst SM, Meniel V, Birkbak NJ, Lau E, Sansregret L, Morelli D, Kanu N, Srinivas S, Graupera M, Parker VER, Montgomery KG, Moniz LS, Scudamore CL, Phillips WA, Semple RK, Clarke A, Swanton C, Vanhaesebroeck B.

Nat Commun. 2017 Nov 24;8(1):1773. doi: 10.1038/s41467-017-02002-4.

Supplemental Content

Support Center